Chemotherapy for ovarian cancer has gone through 3 important phases, namely alkylating agents in the 1970s, cisplatin-based drugs in the 1980s and paclitaxel in the 1990s. In recent years, many new drugs have been introduced, many treatment regimens have been improved, and some views have been gradually updated. However, regular, adequate and timely doses are still the most basic principles of drug administration. Comprehensive staging exploratory surgery is the basic treatment of choice for early-stage ovarian cancer as a way to determine which patients need chemotherapy. Combination chemotherapy, mainly platinum-based, is the preferred adjuvant therapy for early-stage ovarian cancer. The response rate of advanced ovarian cancer to first-line chemotherapy drugs can reach 70% to 80%. Currently, combination chemotherapy with Tysol and carboplatin is recommended as the first-line chemotherapy regimen of choice for ovarian cancer. However, most patients with advanced ovarian cancer are prone to recurrence and may develop drug resistance, making the management of recurrent ovarian cancer clinically more difficult. When developing second-line chemotherapy regimens, patients with drug-resistant, recalcitrant and refractory ovarian cancer are often separated from patients with recurrent cancer who are sensitive to platinum-based agents. However, in general, the treatment of recurrent ovarian cancer generally tends to be conservative. Therefore, when choosing a second-line chemotherapy regimen, the expected toxic effects of the chosen regimen and its impact on overall quality of life should be given focused consideration. Abdominal chemotherapy is the most desirable route of chemotherapy for ovarian cancer, but its exact clinical value has yet to be confirmed by evidence from evidence-based medicine. The value of preemptive chemotherapy is mainly due to its ability to significantly improve the quality of ovarian cancer cytoreduction, but whether it can improve patient survival remains to be further proven. Chemotherapy has an extremely important and irreplaceable position in the treatment of ovarian cancer. However, the process of chemotherapy is prone to drug resistance, resulting in unsatisfactory efficacy. Repeated chemotherapy for drug-resistant cases is currently a hot topic of discussion in the gynecologic oncology field. Combination chemotherapy regimens are mostly used for chemotherapy. All ovarian cancers treated for the first time with chemotherapy are treated with first-line chemotherapy regimens, while recurrent or drug-resistant ovarian cancers are treated with second-line chemotherapy regimens. (1) Indications: First-time chemotherapy, including patients before and after surgery and those without surgical indications. (2) Contraindications: Patients with poor nutritional status, cachexia or survival estimated to be less than 3 months; patients with white blood cells below 4,000×109/L and platelets below 100×109/L; patients with bone marrow metastasis or previous radiation treatment with extensive irradiation to bone marrow; patients with severe renal insufficiency. (3) Combination chemotherapy regimen: CAP regimen: applicable to epithelial class, mesenchymal malignant tumors of the sex cords. Cyclophosphamide 750mg/m2ivd1, Adriamycin 50mg/m2ivd1, Carboplatin 300-350mg/m2 or Cisplatin 75mg/m2ipd1. CP regimen: For early stage epithelial, mesenchymal malignancies. CTX 650-750mg/m2ivd1, Carboplatin 300-350mg/m2 or Cisplatin 75mg/m2ipd1. is the preferred regimen. TP regimen: paclitaxel or Tysol 135-175mg/m2ivd1, carboplatin 300-350mg/m2 or cisplatin 75mg/m2ipd1. All of the above regimens are administered as a course of treatment every four weeks, with 4 consecutive courses after surgery in stage I cases and 8 consecutive courses after satisfactory cytoreductive surgery in intermediate to advanced stages. The blood picture and other chemotherapy side effects must be observed during chemotherapy so that the dose and chemotherapy course can be adjusted.